Evaluation of the Efficacy of the Use MD Tissue Collagen Medical Device in the Infiltrative Treatment of Greater Trochanter Pain Syndrome (GTPS) (MEDANTRO)

Evaluation of the Efficacy of the Use of a Type I Collagen-based MD Tissue Collagen Medical Device in the Infiltrative Treatment of Greater Trochanter Pain Syndrome (GTPS) "MEDANTRO PILOT STUDY"

Greater Trochanteric Pain Syndrome, also known as GTPS (Greater Trochanteric Pain Syndrome) is a complex clinical condition characterized by chronic and recurrent pain in the lateral region of the hip, near the greater trochanter of the femur.

Biomechanical and anatomic-histologic interactions of the structures of the peri trochanteric space, in which, given the close anatomic-functional relationships, the origin can be traced to three different pathologic entities that may influence each other and fuel the progressive exacerbation of symptomatology. These are: external snap hip, trochanteric bursitis, and tendinopathies of the tendons of the gluteus mediums and gluteus minimums muscles.

Recent studies regarding GTPS have shown that in most cases this condition is due to degenerative tendinopathy of the tendons of the gluteus minimums and gluteus mediums muscles. Tendinopathy is defined as a pathological condition associated with histological changes that may result in a change in the organization of collagen fibrils, relative increase in the percentage of proteoglycans, glycosaminoglycans, and no collagenous components of the ECM accompanied by neo-vascularization and inflammatory state.

Tendinopathies thus result in painful symptomatology that very often also results in biomechanical functional deficit.

Clinically, GTPS presents as pain that is often debilitating and exacerbated by activities such as walking, climbing stairs, and lying on the affected side at night, associated with a progressive loss of stenia in hip abduction movements. On objective examination, a point of tenderness (trigger point) is noted at the level of the region of the greater trochanter, which may radiate to the lumbar area and along the lateral aspect of the thigh to the ipsilateral knee and a difficulty on strength versus resistance tests in hip abduction movements.

Although it is a very common syndrome, the treatment of painful grand trochanter syndrome, as well as that of tendinopathies in general, is still a major hurdle because the specific cellular pathogenetic and biomechanical etiopathogenetic mechanisms are still partly unknown and many treatments are empirical. Traditionally, the treatment of GTPS is initially conservative and includes rest, ice, NSAIDs and physiotherapy with stretching exercises of the fascia late. The use of corticosteroids, with systemic or local infiltrative intake, for the treatment of tendinopathies is highly controversial and, in any case, does not seem to have long-term efficacy.

MD-Tissue Collagen Medical Device is an injectable medical device based on porcine collagen type I; the collagen content is 100µg/2mL. Porcine collagen is like human collagen and highly compatible; it has very low risks of inducing adverse effects and is therefore used in several clinical settings.

Study Overview

• Status: Completed
• Conditions: Greater Trochanteric Pain Syndrome; Pertrochanteric Fracture; Gluteal Tendinitis; GTPS - Greater Trochanteric Pain Syndrome; Tendon Disorder; Gluteal Muscles
• Intervention / Treatment: Device: MD Tissue Collagen Medical Device

Detailed Description

This is a pilot monocentric Clinical Investigation based on a One sample design.

In the ex vivo study, MD-Tissue Collagen Medical Device was used as a substrate for cell cultures of human gluteal tenocytes on culture plates. The results suggest how MD-Tissue can induce an anabolic phenotype in tenocytes by stimulating their proliferation and migration; it would also be able to promote the synthesis, maturation, and secretion of COL-I, thereby promoting tendon homeostasis and repair. Specifically, the modification of gene expression and proteins involved in collagen turnover pathways were analyzed by real-time PCR, Slot blot and SDS-zymography. Data from the study showed that tenocytes cultured with MD-Tissue compared with controls exhibited increased secretion and migration of COL-1 increased mRNA levels of the matrix metalloprotease inhibitor proteins MMP-1 and TIMP-1.

The tenocytes used for the cell cultures were gluteal tenocytes, derived from human gluteal tendon fragments (obtained from subjects without any tendon pathology who had undergone total hip replacement surgery); therefore, it is reasonable to think that the porcine type I collagen-based compound may be a viable treatment in GTPS.

The results of the preclinical study suggest how MD-Tissue Collagen Medical Device can induce an anabolic phenotype in tenocytes by stimulating tenocyte proliferation and COL-I synthesis, maturation, and secretion, thereby promoting tendon repair. As these effects have been evaluated ex vivo on tenocytes of gluteal muscle tendons, the purpose of this study is to evaluate its efficacy in local infiltrative treatment, in the pertechnetic region, of GTPS, in terms of resolution of pain symptoms and recovery of stenia in abduction.

Variables will be assessed at 6 different times; at baseline (day 0), after week 1, weeks 2, weeks 6, weeks 10 and after weeks 24.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • MI
    • Milan, MI, Italy, 20122
      • Gaetano Pini CTO

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male and female subjects aged 18 to 70 years;
• subjects with lateral palpatory pain that has appeared for at least 1 month;
• subjects with hip pain symptomatology assessed by Numerical rating scale (NRS) ≥ to 5;
• Subjects able to cooperate for the assessments in the Survey plan;
• subjects able to understand and sign informed consent.

Exclusion Criteria:

• subjects with true coxalgia (with positive FADDIR);
• subjects with ESHS (external snap hip syndrome);
• subjects already undergoing candidate hip replacement surgery;
• subjects with radiologic and clinical evidence of small and/or middle gluteal tendon detachment with indication for surgical repair;
• subjects with evidence of radiographically documented tendon calcifications;
• subjects with a degree of coxarthrosis of the hip that is a candidate for treatment according to the classification of Tonnis>1
• subjects who have taken fluoroquinolones within 30 days prior to enrollment
• subjects who have undergone treatment with hyaluronic acid or corticosteroids in the hip candidate for infiltrative treatment within 4 weeks before enrollment;
• subjects with local infections of the treatment candidate hip or systemic infections, osteomyelitis, or sepsis;
• subjects on chronic treatment with corticosteroids or immunosuppressants;
• subjects who are drug addicts, alcoholics, have psychiatric disorders, or have clinical conditions that may compromise the correct interpretation of PROMs or follow-up;
• subjects with coagulopathies, platelet aggregation disorders, or on treatment with oral anticoagulants or antiplatelets that cannot be discontinued during the study period;
• Pregnant and lactating subjects (female subjects of childbearing age should be tested for pregnancy before enrollment);
• subjects with allergy to porcine collagen.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: MD-Tissue Medical Device

Device: MD Tissue Collagen Medical Device; The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode. MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in NRS (Numerical Rating Scale) Pain Score From Baseline (Week 0) to Week 10	Pain intensity was measured using the NRS (Numerical Rating Scale), a validated scale ranging from 0 (no pain) to 10 (worst possible pain). Participants were asked to indicate their pain level at baseline (Week 0) and at Week 10. A change of at least 3 points on the NRS is considered clinically significant. The primary outcome is the mean change in NRS score from baseline to Week 10.	weeks 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean NRS (Numerical Rating Scale) Pain Score at Week 6 and Week 24 Compared to Baseline (T0)	Pain intensity was measured using the NRS (Numerical Rating Scale) at rest, ranging from 0 (no pain) to 10 (worst possible pain). Participants were asked to rate their pain at baseline (T0), week 6 (T6w/FU), and week 24 (T24w/FU). This outcome reports the mean NRS values at week 6 and 24. Higher scores indicate more intense pain.	weeks 6 and weeks 24
Change in Modified Harris Hip Score (mHHS) From Baseline to Weeks 6, 10, and 24	The Modified Harris Hip Score (mHHS) is a validated tool for assessing hip function and pain. It ranges from 0 (worst functional outcome and highest pain) to 100 (best function and least pain). Participants were evaluated at Weeks 6, 10, and 24 compared to baseline. The change in total score is used to assess clinical improvement. Unit of Measure: Score from 0 to 100; higher scores indicate better outcome	Weeks 6, 10, and 24
Change in Hip Abduction Strength From Baseline to Weeks 6, 10, and 24	Hip abduction strength was assessed using a handheld dynamometer at Weeks 6, 10, and 24. The measurement was performed with the patient standing on the contralateral (healthy) limb, while abducting the hip affected by GTPS. For each assessment, three consecutive measurements were taken and averaged. Results were compared to baseline (Day 0) to evaluate functional improvement in muscular strength.	Weeks 6, 10, and 24
MRI Evaluation of Inflammatory and Degenerative Signs in the Peritrochanteric Region at Week 24 Compared to Baseline	MRI evaluation focused on inflammatory and degenerative signs in the peritrochanteric region (gluteus medius/minimus tendons) was conducted at Week 24 and compared to baseline (Week 0). Two independent radiologists assessed peri-tendinous fluid and intra-tendinous edema on STIR-weighted images. Improvement was defined as visible reduction in peritendinous edema. The analysis was qualitative and dichotomous (Improved vs. Unchanged).	Week 24 compared to baseline (Week 0)
Change in Analgesic Drug Consumption (Paracetamol and/or Celecoxib) From Baseline to Week 24	Analgesic drug consumption (paracetamol and/or celecoxib) was recorded using a patient diary at time points T0 (baseline), T1w, T2w, T6w/FU, T10w/FU, and T24w/FU. Each patient logged the number of analgesic doses consumed per week. The total number of doses per timepoint was used to assess any significant change over time. The analysis aimed to evaluate whether the treatment reduced the need for pain medication, as an indirect marker of clinical efficacy. Unit of measure: Number of analgesic doses consumed per week.	Week 1, Week 2, Week 6, Week 10, and Week 24 compared to baseline (Week 0) Week 1, Week 2, Week 6, Week 10, and Week 24 compared to baseline (Week 0) Week 1, Week 2, Week 6, Week 10, and Week 24 compared to baseline (Week 0)
Incidence of Adverse Events (AE, SAE, SUSAR) From Baseline to Week 24	Adverse events (AEs), serious adverse events (SAEs), and suspected unexpected serious adverse reactions (SUSARs) were monitored at each study visit from baseline (Day 0) to Week 24. Data were collected via systematic interviews and clinical assessments. No adverse events of any type were reported during the study. AE definitions followed ICH-GCP and ClinicalTrials.gov guidance.	Day 0 to Week 24

Collaborators and Investigators

• Sponsor: Guna S.p.a
• Investigators: Principal Investigator: Randelli RFMN Filippo Maria Nicola, Prof, Gaetano Pini CTO

Study record dates

Study Major Dates

• Study Start (Actual): September 13, 2021
• Primary Completion (Actual): May 31, 2023
• Study Completion (Actual): May 31, 2023

Study Registration Dates

• First Submitted: July 4, 2022
• First Submitted That Met QC Criteria: August 1, 2022
• First Posted (Actual): August 3, 2022

Study Record Updates

• Last Update Posted (Actual): July 14, 2025
• Last Update Submitted That Met QC Criteria: July 11, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Numeric Rating Scale; Type I collagen; MD-Tissue Collagen Medical; Ecoguide; Biomechanical; Modified Harris Hip Score
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Muscular Diseases; Mental Disorders; Wounds and Injuries; Pathologic Processes; Joint Diseases; Disease; Tendon Injuries; Somatoform Disorders; Syndrome; Bursitis; Tendinopathy
• Other Study ID Numbers: MDG2020711

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No